treatment of immune thrombocytopenia (ITP) – CRI Report https://www.cri-report.com market research vender! Thu, 02 Dec 2021 07:18:50 +0000 en-US hourly 1 https://www.cri-report.com/wp-content/uploads/2021/01/cropped-shcrilogo-c.jpg treatment of immune thrombocytopenia (ITP) – CRI Report https://www.cri-report.com 32 32 Investigation Report on China’s Recombinant human thrombopoietin (rhTPO) Market 2021-2025 https://www.cri-report.com/investigation-report-on-chinas-recombinant-human-thrombopoietin-rhtpo-market-2021-2025/ Tue, 08 Jun 2021 05:56:54 +0000 https://www.cri-report.com/?post_type=product&p=11766 In 2020, due to the impact of the COVID-19 epidemic on the overall diagnosis and treatment services of hospitals in China, its sales growth has slowed, but the sales value of rhTPO in the Chinese market still reached CNY1.3 billion, and the CAGR was 32.44% in 2016 to 2020.

The post Investigation Report on China’s Recombinant human thrombopoietin (rhTPO) Market 2021-2025 first appeared on CRI Report.

]]> Recombinant Human Thrombopoietin(rhTPO), developed by Shenyang Sansheng Pharmaceutical Co., Ltd., was approved for marketing in China in 2005 and used to treat thrombocytopenia caused by chemotherapy. It was approved for the treatment of immune thrombocytopenia (ITP) in 2010. In 2017, it was included in the National Medical Insurance Drug List of Western Medicine Partial Medical Insurance Category B. By 2020, Shenyang Sansheng Pharmaceutical Co., Ltd. is the only manufacturer in China’s rhTPO market.

According to CRI’s market research, the sales value of rhTPO in the Chinese market has increased year by year from 2016 to 2020. In 2020, due to the impact of the COVID-19 epidemic on the overall diagnosis and treatment services of hospitals in China, its sales growth has slowed, but the sales value of rhTPO in the Chinese market still reached CNY1.3 billion, and the CAGR was 32.44% in 2016 to 2020.

CRI expects that with the effective relief of the COVID-19 epidemic in 2021-2025, the sales of rhTPO will increase. In addition, the cancer incidence rate in China has maintained an annual increase of about 3.9% in the past 10 years. Therefore, the sales volume of rhTPO used to treat cancer and other chemotherapy-induced thrombocytopenia will increase with the increase in the number of cancer patients. At the same time, TPIAO’s patent has expired, and many companies in China have applied for approval for clinical trials of generic drugs. It is expected that new manufacturers will join the rhTPO market in the next five years, and sales will grow in the future.

Topics Covered:
-The impact of COVID-19 on China’s Recombinant Human Thrombopoietin(rhTPO) market
– Sales value of China’s Recombinant Human Thrombopoietin(rhTPO) 2016-2020
– Competitive landscape of China’s Recombinant Human Thrombopoietin(rhTPO) market
– Prices of Recombinant Human Thrombopoietin(rhTPO) in China
– Prices of Recombinant Human Thrombopoietin(rhTPO) in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Recombinant Human Thrombopoietin(rhTPO) market
– Prospect of China’s Recombinant Human Thrombopoietin(rhTPO) market from 2021 to 2025

The post Investigation Report on China’s Recombinant human thrombopoietin (rhTPO) Market 2021-2025 first appeared on CRI Report.

]]>